Last updated: November 7, 2026
Cabozantinib laurylsulfate, marketed in the United States as Cabometyx by Exelixis, is a commercially established multikinase inhibitor with major exposure to renal cell carcinoma. Its financial trajectory has been driven by label expansion, combination use with nivolumab, higher treatment duration and international licensing. The product remains commercially durable, but its long-term value depends on patent protection, generic-entry settlements and the ability to defend share against immune checkpoint combinations, lenvatinib, tivozanib and other targeted therapies.
Exelixis reported total revenue of approximately $1.85 billion in 2023, compared with $1.58 billion in 2022 and $1.36 billion in 2021. Cabometyx was the company’s central commercial asset and accounted for most of its product revenue.[1]
What is cabozantinib laurylsulfate and how is it marketed?
Cabozantinib laurylsulfate is the active pharmaceutical ingredient in Cabometyx tablets. The drug inhibits multiple kinases, including MET, VEGFR, AXL, RET and several related signaling targets. It is distinct from Cometriq, the capsule formulation of cabozantinib used for medullary thyroid cancer. Cometriq contains cabozantinib as the S-malate salt, while Cabometyx contains the laurylsulfate salt.
| Product |
Active ingredient form |
Primary U.S. indication |
Commercial company |
| Cabometyx |
Cabozantinib laurylsulfate |
Renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer |
Exelixis |
| Cometriq |
Cabozantinib S-malate |
Progressive metastatic medullary thyroid cancer |
Exelixis |
| Cabozantinib plus nivolumab |
Cabometyx with Opdivo |
First-line advanced renal cell carcinoma |
Exelixis and Bristol Myers Squibb |
Cabometyx is supplied as oral tablets in 20 mg, 40 mg and 60 mg strengths. The standard RCC dose is 60 mg once daily as monotherapy. When combined with nivolumab, the Cabometyx dose is generally 40 mg once daily, reflecting tolerability considerations in combination treatment.[2]
What FDA-approved indications support Cabometyx demand?
Cabometyx has three principal U.S. demand drivers.
Renal cell carcinoma
The FDA initially approved Cabometyx in 2016 for advanced RCC in patients previously treated with an antiangiogenic therapy. In 2018, the FDA expanded the label to include first-line treatment of advanced RCC in combination with nivolumab.[2]
The RCC franchise remains the largest source of Cabometyx demand. The product competes in several treatment settings:
- First-line combination therapy with nivolumab
- Later-line monotherapy after prior VEGFR-targeted treatment
- Use after immune checkpoint therapy
- Treatment of patients who require an oral VEGFR/MET-targeted option
The nivolumab combination broadened the addressable market from previously treated RCC to newly diagnosed advanced disease. It also increased the strategic importance of Cabometyx because the product became part of a branded regimen rather than only a later-line monotherapy.
Hepatocellular carcinoma
The FDA approved Cabometyx in 2019 for patients with hepatocellular carcinoma previously treated with sorafenib.[2] The indication creates a second oncology market but has a smaller commercial contribution than RCC.
Cabometyx competes with regorafenib, lenvatinib, cabozantinib alternatives in clinical development and immune checkpoint-based regimens. HCC treatment sequencing is complex, and product uptake depends on prior therapy, liver function, performance status and payer restrictions.
Differentiated thyroid cancer
The FDA approved Cabometyx in 2021 for adults with locally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy and is refractory to radioactive iodine or unsuitable for radioactive iodine treatment.[2]
This indication is commercially meaningful but narrower than RCC. It provides additional lifecycle protection and creates a targeted option for patients who have exhausted radioactive iodine and VEGFR-based treatment.
How has the financial trajectory of cabozantinib developed?
Exelixis has moved from a single-product biotechnology company toward a cash-generating oncology company anchored by cabozantinib. Reported total revenue increased as follows:
| Fiscal year |
Exelixis total revenue |
Year-over-year change |
| 2021 |
Approximately $1.36 billion |
- |
| 2022 |
Approximately $1.58 billion |
Approximately 16% |
| 2023 |
Approximately $1.85 billion |
Approximately 17% |
Source: Exelixis annual reports and Form 10-K filings.[1]
The principal drivers were:
- Continued Cabometyx growth in the United States.
- Expansion of first-line RCC use with nivolumab.
- Royalty and collaboration revenue from international commercialization.
- Higher use of cabozantinib in patients receiving multiple lines of therapy.
- Increased commercial productivity from a mature oncology sales infrastructure.
Exelixis has also benefited from a licensing model. Ipsen holds rights to commercialize cabozantinib outside the United States and Japan in many markets, while Takeda has had rights in Japan. These arrangements reduce Exelixis’s direct international commercial costs and generate royalties or collaboration revenue.[1]
Revenue exposure
Cabometyx creates concentration risk. A large portion of Exelixis revenue depends on one active ingredient, one core commercial franchise and the continued absence of broad generic competition. That concentration supports strong operating leverage while increasing the effect of patent litigation, safety changes, reimbursement pressure or clinical displacement.
The company has attempted to reduce this exposure through pipeline programs, including zanzalintinib and other oncology candidates. Those programs are important for post-cabozantinib growth but do not currently replace Cabometyx’s revenue scale.
What patents protect cabozantinib laurylsulfate?
Cabometyx is protected by a layered patent estate covering the active compound, salt form, solid-state properties, pharmaceutical compositions, dosing and methods of use. The Orange Book is the principal U.S. source for listed patents and exclusivity information.[3]
Patent categories
| Protection category |
Commercial relevance |
| Cabozantinib chemical compound patents |
Protect the underlying kinase inhibitor |
| Laurylsulfate salt patents |
Protect the specific active ingredient used in Cabometyx |
| Crystalline and solid-state patents |
Can restrict manufacture of the commercial form |
| Tablet and formulation patents |
Cover drug composition and dosage-form attributes |
| Method-of-use patents |
Cover treatment of RCC, HCC and differentiated thyroid cancer |
| Combination-use patents |
May cover cabozantinib with immune checkpoint inhibitors |
| Manufacturing patents |
Can increase the cost and complexity of non-infringing production |
Publicly reported U.S. patent protection for Cabometyx extends into the late 2020s and, for certain listed patents and use claims, into the early 2030s. The precise date depends on the patent, patent-term adjustment, terminal disclaimers, pediatric extension and the claims asserted in litigation. Patent expiration should therefore be evaluated patent by patent rather than through a single “Cabometyx expiration date.”[3]
Exelixis has historically relied on Orange Book-listed patents and litigation to defend against abbreviated new drug applications. Formulation and method-of-use patents are particularly important because an ANDA applicant may attempt to avoid infringement through a Paragraph IV certification, a section viii carve-out or a different label.
When does Cabometyx lose exclusivity?
Cabometyx does not have one uniform loss-of-exclusivity date.
The commercial sequence is likely to involve:
- Patent challenges to core compound or salt claims.
- Litigation over formulation and solid-state claims.
- Disputes concerning RCC, HCC or thyroid-cancer methods of use.
- Potential settlement agreements that establish an authorized or licensed generic entry date.
- Later exposure to additional generic manufacturers after the principal settlement period.
The economic loss from generic entry may be gradual rather than immediate. Oral oncology products can experience rapid price erosion, but the pace depends on the number of approved entrants, payer substitution, specialty-pharmacy controls, supply reliability and whether the brand retains use in combination regimens.
The strongest protection is generally the later-expiring valid claim that covers the commercial product or an unavoidable indication. A method-of-use patent can delay generic access to a particular indication but may not prevent a skinny-label generic from entering for unpatented uses.
Which companies are challenging Cabometyx patents?
Cabometyx has attracted ANDA-related patent disputes involving generic drug manufacturers. Publicly disclosed litigation and patent records have included challenges by companies such as Teva, Sun Pharmaceutical Industries, Cipla, Zydus and Dr. Reddy’s Laboratories, although the status and scope of individual cases can change through dismissals, amended pleadings, settlements or confidential agreements.
A Paragraph IV certification alleges that an Orange Book patent is invalid, unenforceable or not infringed. Filing an ANDA with a Paragraph IV certification can trigger a 30-month stay of FDA approval if the brand company files a timely patent-infringement action under the Hatch-Waxman Act.[4]
The key commercial questions are:
- Whether the challenger attacks the active ingredient, salt, formulation or method-of-use claims.
- Whether the case reaches trial or settles.
- Whether the settlement permits a defined launch date.
- Whether the settlement includes a license, authorized generic rights or supply terms.
- Whether a court invalidates the asserted claims before the negotiated entry date.
Public litigation activity indicates meaningful generic interest, but it does not by itself establish an imminent generic launch. FDA approval, litigation outcomes and settlement terms determine the actual entry risk.
What is the Orange Book status of Cabometyx?
Cabometyx is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Listed patents may cover the drug substance, drug product, formulation or approved methods of use.[3]
Orange Book review should distinguish:
- Patents listed against Cabometyx rather than Cometriq.
- Active patents from expired patents.
- Product patents from use patents.
- Patent expiration from pediatric exclusivity.
- FDA approval eligibility from commercial launch eligibility.
The FDA’s Orange Book does not decide patent validity or infringement. It records sponsor-submitted patent information and provides the regulatory framework for ANDA certifications. Federal courts determine infringement and validity.
How strong is the cabozantinib patent estate?
The estate is commercially strong but not immune to erosion.
Strengths
- Multiple indication-specific revenue streams.
- A differentiated salt and tablet product.
- Long-term use in RCC, where treatment duration can be substantial.
- Combination use with nivolumab.
- Several potential layers of composition, formulation and method-of-use protection.
- High clinical and regulatory barriers to demonstrating equivalent therapeutic use across oncology indications.
Weaknesses
- The underlying molecule is well characterized.
- Generic manufacturers can target individual claims rather than the entire product.
- Method-of-use patents may be vulnerable to skinny-label strategies.
- Multiple approved treatments reduce the commercial impact of a single generic entrant.
- Patent litigation can invalidate selected claims even if other claims survive.
The estate is stronger than a single-use patent portfolio but weaker than a biologic exclusivity position that depends on complex manufacturing and interchangeability barriers.
How does Cabometyx compare with competing kidney-cancer drugs?
| Drug or regimen |
Company |
Main commercial position |
Competitive effect on Cabometyx |
| Cabometyx plus nivolumab |
Exelixis/Bristol Myers Squibb |
First-line advanced RCC |
Supports market expansion |
| Pembrolizumab plus axitinib |
Merck/Pfizer |
First-line advanced RCC |
Major frontline competitor |
| Pembrolizumab plus lenvatinib |
Merck/Eisai |
First-line advanced RCC |
Competes on efficacy and combination use |
| Nivolumab plus ipilimumab |
Bristol Myers Squibb |
First-line advanced RCC |
Competes for favorable-risk and intermediate/poor-risk patients |
| Lenvatinib |
Eisai |
RCC combination and later-line use |
Competes in targeted therapy |
| Tivozanib |
Aveo, now LG Chem |
Later-line RCC |
Competes for VEGFR-focused treatment |
| Axitinib |
Pfizer |
RCC targeted treatment |
Established alternative |
| Pazopanib and sunitinib |
Novartis and Pfizer |
Earlier-generation RCC therapies |
Lower-cost and historical alternatives |
Cabometyx’s main commercial advantage is its combination of VEGFR, MET and AXL inhibition. Its major disadvantage is treatment tolerability, including diarrhea, palmar-plantar erythrodysesthesia, fatigue, hypertension, appetite loss and dose reductions. Treatment discontinuation and dose modification can limit net revenue per patient even when gross demand remains strong.[2]
What generic entry risks exist for Cabometyx?
Generic entry risk is material but timing-dependent.
Near-term risk
Near-term risk is driven by Paragraph IV litigation, settlement terms and the survival of key Orange Book claims. A court decision against a core patent could accelerate entry. A settlement could establish a later, controlled entry date and reduce binary litigation risk.
Medium-term risk
The medium-term risk is higher because several generic manufacturers may pursue different claim strategies. One applicant may challenge the drug substance, while another targets tablet composition or a method-of-use patent.
Post-entry commercial risk
After entry, the most exposed revenue would likely be:
- Monotherapy prescriptions with straightforward substitution.
- Price-sensitive payer channels.
- Later-line use where clinical differentiation is limited.
- Indications that lack a protected combination or narrow-label strategy.
Combination therapy and complex treatment sequencing may slow substitution, but branded Cabometyx would still face price and formulary pressure.
What biosimilar risk applies to cabozantinib?
Cabometyx has no conventional biosimilar risk because it is a chemically synthesized small-molecule drug, not a biologic. The relevant threat is generic-drug entry through the ANDA pathway.
Nivolumab, the principal combination partner, is a biologic and may eventually face biosimilar competition through the biologics regulatory framework. That risk would affect the economics of the combination regimen, but it is separate from Cabometyx’s own regulatory exclusivity.
What licensing deals affect cabozantinib revenue?
Exelixis has used regional partnerships to commercialize cabozantinib outside the United States. Ipsen has held broad ex-U.S. rights, while Takeda has been associated with commercialization in Japan. These agreements provide:
- Upfront and milestone economics.
- Royalties or profit-sharing.
- Lower direct selling costs outside the United States.
- Broader geographic access.
- Reduced international operating exposure.
The tradeoff is that Exelixis does not capture the full end-market revenue in licensed territories. Reported financial results therefore include a mixture of U.S. product revenue, collaboration revenue, royalties and milestone-related income.[1]
What is the outlook for the cabozantinib market?
Cabometyx should remain a major Exelixis revenue source while RCC demand continues to expand and generic entry remains blocked or controlled. Growth is likely to moderate as the product matures and frontline RCC competition intensifies.
The principal value drivers are:
- Continued adoption of cabozantinib plus nivolumab.
- Duration of U.S. patent protection.
- Outcome of ANDA litigation.
- Timing and terms of generic settlements.
- International royalty growth.
- Cabozantinib use after immune checkpoint therapy.
- Successful development of next-generation Exelixis assets.
The principal downside risks are:
- Earlier-than-expected generic entry.
- Patent invalidation.
- Pricing pressure from competing oral kinase inhibitors.
- Dose reductions and treatment discontinuation.
- Weak differentiation in HCC or thyroid cancer.
- Dependence on one core commercial molecule.
Key Takeaways
- Cabozantinib laurylsulfate is marketed as Cabometyx and is Exelixis’s primary commercial product.
- RCC, particularly first-line use with nivolumab, is the main demand and revenue driver.
- Exelixis total revenue rose from approximately $1.36 billion in 2021 to $1.85 billion in 2023.
- Cabometyx has a layered patent estate covering the active ingredient, salt, formulation, solid-state properties and methods of use.
- U.S. patent protection extends into the late 2020s and, for selected claims, into the early 2030s.
- Generic risk comes through ANDA Paragraph IV challenges rather than biosimilar competition.
- Teva, Sun, Cipla, Zydus and Dr. Reddy’s have been associated with Cabometyx-related generic challenges or litigation activity.
- The commercial outlook remains strong, but revenue concentration and eventual generic entry create substantial downside exposure.
- The most important valuation variable is the negotiated or adjudicated date for meaningful generic entry.
FAQs
Is Cabometyx the same as Cometriq?
No. Both contain cabozantinib, but Cabometyx contains cabozantinib laurylsulfate tablets, while Cometriq contains cabozantinib S-malate capsules. They have different formulations, strengths and FDA-approved uses.
Does Cabometyx have biosimilar competition?
No. Cabometyx is a small-molecule drug. Competition would arise through generic ANDA approvals rather than biosimilar applications.
Which cancer generates most Cabometyx sales?
Renal cell carcinoma generates most of the commercial demand. The largest strategic expansion came from first-line Cabometyx plus nivolumab.
Can a generic company launch Cabometyx before all patents expire?
Potentially, but only if it prevails in litigation, obtains a license, reaches a settlement permitting earlier entry or launches after certifying that relevant patents do not block approval and commercialization.
What is the biggest financial risk to Exelixis?
The largest risk is loss of Cabometyx exclusivity before replacement products generate comparable revenue. Because Cabometyx accounts for a substantial share of Exelixis’s economics, an accelerated generic launch could materially affect revenue, margins and cash flow.
References
-
Exelixis, Inc. (2024). 2023 annual report and Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Cabometyx prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
